Dr. Siobh?n N? Bhriain:

I will first respond to the Deputy's question about Evusheld, if that is okay. Evusheld is currently undergoing a health technology assessment, HTA. It is still an investigational medication internationally. The evidence in its favour does not yet fully support its use in this country. It is undergoing that HTA and we expect the results of that in due course. That has been advised by the medicines management programme. There is a recently emerging body of evidence that it may not be so effective for patients who have more recent variants. We are waiting for results before we subject our patients to medication that may cause other risks and damages. I could not agree more with the Deputy that immunocompromised patients have had an enormously difficult time during the pandemic.